202 related articles for article (PubMed ID: 29654898)
1. Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies.
Sun J; Bao H; Peng Y; Zhang H; Sun Y; Qi J; Zhang H; Gao Y
Int J Pharm; 2018 Jun; 544(1):46-54. PubMed ID: 29654898
[TBL] [Abstract][Full Text] [Related]
2. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge.
Xu HY; Liu CS; Huang CL; Chen L; Zheng YR; Huang SH; Long XY
Colloids Surf B Biointerfaces; 2019 Sep; 181():927-934. PubMed ID: 31382342
[TBL] [Abstract][Full Text] [Related]
3. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Shan YQ; Zhu YP; Pang J; Wang YX; Song DQ; Kong WJ; Jiang JD
Biol Pharm Bull; 2013; 36(10):1562-9. PubMed ID: 23924821
[TBL] [Abstract][Full Text] [Related]
4. Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.
Shan YQ; Ren G; Wang YX; Pang J; Zhao ZY; Yao J; You XF; Si SY; Song DQ; Kong WJ; Jiang JD
Metabolism; 2013 Mar; 62(3):446-56. PubMed ID: 23079743
[TBL] [Abstract][Full Text] [Related]
5. Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine.
Xiong W; Sang W; Linghu KG; Zhong ZF; Cheang WS; Li J; Hu YJ; Yu H; Wang YT
Int J Nanomedicine; 2018; 13():3781-3793. PubMed ID: 29988733
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Wang Y; Campbell T; Perry B; Beaurepaire C; Qin L
Metabolism; 2011 Feb; 60(2):298-305. PubMed ID: 20304443
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats.
Chen W; Miao YQ; Fan DJ; Yang SS; Lin X; Meng LK; Tang X
AAPS PharmSciTech; 2011 Jun; 12(2):705-11. PubMed ID: 21637946
[TBL] [Abstract][Full Text] [Related]
8. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
9. Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO₂: preparation, characterization and in vivo studies.
Zhang Z; Chen Y; Deng J; Jia X; Zhou J; Lv H
Int J Pharm; 2014 Apr; 465(1-2):306-16. PubMed ID: 24456672
[TBL] [Abstract][Full Text] [Related]
10. Transforming berberine into its intestine-absorbable form by the gut microbiota.
Feng R; Shou JW; Zhao ZX; He CY; Ma C; Huang M; Fu J; Tan XS; Li XY; Wen BY; Chen X; Yang XY; Ren G; Lin Y; Chen Y; You XF; Wang Y; Jiang JD
Sci Rep; 2015 Jul; 5():12155. PubMed ID: 26174047
[TBL] [Abstract][Full Text] [Related]
11. Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.
Dou Y; Huang R; Li Q; Liu Y; Li Y; Chen H; Ai G; Xie J; Zeng H; Chen J; Luo C; Su Z
Biomed Pharmacother; 2021 May; 137():111312. PubMed ID: 33524788
[TBL] [Abstract][Full Text] [Related]
12. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.
Xue M; Yang MX; Zhang W; Li XM; Gao DH; Ou ZM; Li ZP; Liu SH; Li XJ; Yang SY
Int J Nanomedicine; 2013; 8():4677-87. PubMed ID: 24353417
[TBL] [Abstract][Full Text] [Related]
13. In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications.
Di S; Han L; An X; Kong R; Gao Z; Yang Y; Wang X; Zhang P; Ding Q; Wu H; Wang H; Zhao L; Tong X
J Ethnopharmacol; 2021 Aug; 276():114180. PubMed ID: 33957209
[TBL] [Abstract][Full Text] [Related]
14. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Pirillo A; Catapano AL
Atherosclerosis; 2015 Dec; 243(2):449-61. PubMed ID: 26520899
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota.
Lyu Y; Zhang Y; Yang M; Lin L; Yang X; Cheung SCK; Shaw PC; Chan PKS; Kong APS; Zuo Z
Life Sci; 2019 Oct; 235():116818. PubMed ID: 31473193
[TBL] [Abstract][Full Text] [Related]
16. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats.
Lu SS; Yu YL; Zhu HJ; Liu XD; Liu L; Liu YW; Wang P; Xie L; Wang GJ
J Endocrinol; 2009 Feb; 200(2):159-65. PubMed ID: 18996945
[TBL] [Abstract][Full Text] [Related]
17. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption.
Wang Y; Yi X; Ghanam K; Zhang S; Zhao T; Zhu X
Metabolism; 2014 Sep; 63(9):1167-77. PubMed ID: 25002181
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
[TBL] [Abstract][Full Text] [Related]
19. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats.
Lin Y; Shen Q; Katsumi H; Okada N; Fujita T; Jiang X; Yamamoto A
Biol Pharm Bull; 2007 Jul; 30(7):1301-7. PubMed ID: 17603171
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine.
Lv XY; Li J; Zhang M; Wang CM; Fan Z; Wang CY; Chen L
AAPS PharmSciTech; 2010 Mar; 11(1):372-82. PubMed ID: 20237966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
